1. Metabolic Enzyme/Protease
  2. RAR/RXR
  3. Palovarotene

Palovarotene (Synonyms: R 667; Ro 3300074)

Cat. No.: HY-14799 Purity: 99.49%
Handling Instructions

Palovarotene is a nuclear retinoic acid receptor γ (RAR-γ) agonist.

For research use only. We do not sell to patients.

Palovarotene Chemical Structure

Palovarotene Chemical Structure

CAS No. : 410528-02-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 176 In-stock
Estimated Time of Arrival: December 31
5 mg USD 160 In-stock
Estimated Time of Arrival: December 31
10 mg USD 260 In-stock
Estimated Time of Arrival: December 31
50 mg USD 950 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1600 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 8 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review


Palovarotene is a nuclear retinoic acid receptor γ (RAR-γ) agonist.

IC50 & Target


In Vivo

Palovarotene suppresses post-traumatic chondrogenesis and osteogenesis and mitigated trauma-induced ectopic bone formation. Palovarotene inhibits subcutaneous and intramuscular heterotopic ossification (HO) in mice. Palovarotene is given orally for 14 days at 1 mg/kg/day starting on post-operative day (POD) 1 or POD-5, and HO amount, wound dehiscence and related processes are monitored for up to 84 days post injury. Compared to vehicle-control animals, Palovarotene significantly decreases HO by 50 to 60% regardless of when the treatment started and if infection is present[1]. Starting from day 1 of injury, half of the Acvr1cR206H/+ mice are treated with Palovarotene by daily gavage for 14 days and the other half received vehicle as control. Analysis by mCT and 3D image reconstruction at day 14 shows that large HO tissue masses have formed in the targeted leg of Acvr1cR206H/+ mutant mice receiving vehicle, but HO formation is greatly diminished in Palovarotene-treated companions by more than 80% based on bone volume/total volume quantification[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight









Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (60.31 mM; Need ultrasonic)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4123 mL 12.0616 mL 24.1231 mL
5 mM 0.4825 mL 2.4123 mL 4.8246 mL
10 mM 0.2412 mL 1.2062 mL 2.4123 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.03 mM); Clear solution

*All of the co-solvents are provided by MCE.
Animal Administration

A total of 110 young adult pathogen-free male Sprague Dawley rats (Rattus norvegicus; 400-600 g) are used. Rats receive via oral gavage (100 μL) either Palovarotene (1.0 mg/kg) or vehicle as control (5% DMSO in corn oil) prepared every other day for 14 days, starting at postoperative day 1 (POD-1) or POD-5. Rats are euthanized at indicated time points post-injury for ex vivo end point analysis by micro-computed CT (μCT), histology and RT-PCR gene transcript expression.
One-month-old Acvr1cR206H/+ mice are provided doxycycline chow for 3 days to induce mutant gene expression globally. Mouse quadriceps muscles are injured by injection with 50 mL of 10mM cardiotoxin. Beginning on the day of injury, Palovarotene or vehicle (1:4 DMSO in corn oil) is administered daily for 14 days by oral gavage (100 mg/mouse from days 1 to 3 and 15mg/mouse from days 4 to 14) using a 20-gauge gavage needle. Palovarotene solution in DMSO is stored at -20°C under argon and diluted (1:4) with corn oil for administration.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Purity: 99.49%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


PalovaroteneR 667 Ro 3300074R667R-667Ro3300074Ro 3300074Ro-3300074RAR/RXRAutophagyRetinoic acid receptorsRetinoid X receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Department *


Requested quantity *

Country or Region *



Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:
MCE Japan Authorized Agent: